{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:31:27Z","timestamp":1782815487560,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel therapeutics are required for improving the management of chronic inflammatory diseases. Aptamers are single-stranded RNA or DNA molecules that have recently shown utility in a clinical setting, as they can specifically neutralize biomedically relevant proteins, particularly cell surface and extracellular proteins. The nuclear chromatin protein DEK is a secreted chemoattractant that is abundant in the synovia of patients with juvenile idiopathic arthritis (JIA). Here, we show that DEK is crucial to the development of arthritis in mouse models, thus making it an appropriate target for aptamer-based therapy. Genetic depletion of DEK or treatment with DEK-targeted aptamers significantly reduces joint inflammation <jats:italic>in vivo<\/jats:italic> and greatly impairs the ability of neutrophils to form neutrophil extracellular traps (NETs). DEK is detected in spontaneously forming NETs from JIA patient synovial neutrophils, and DEK-targeted aptamers reduce NET formation. DEK is thus key to joint inflammation, and anti-DEK aptamers hold promise for the treatment of JIA and other types of arthritis.<\/jats:p>","DOI":"10.1038\/ncomms14252","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T13:46:27Z","timestamp":1486388787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis"],"prefix":"10.1038","volume":"8","author":[{"given":"Nirit","family":"Mor-Vaknin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1464","authenticated-orcid":false,"given":"Carmelo","family":"Carmona-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Asif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Rabquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta J.","family":"Gonzales-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jorns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilakshmi","family":"Yalavarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave A.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Angevine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley J.","family":"Almburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa E.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Engelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana J.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Markovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"BFncomms14252_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.21659","volume":"64","author":"DI Daikh","year":"2012","unstructured":"Daikh, D. I. & St Clair, E. W. Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road. Arthritis care res. 64, 648\u2013651 (2012).","journal-title":"Arthritis care res."},{"key":"BFncomms14252_CR2","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1038\/mtna.2014.21","volume":"3","author":"J Zhou","year":"2014","unstructured":"Zhou, J. & Rossi, J. J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. ther. Nucleic acids 3, e169 (2014).","journal-title":"Mol. ther. Nucleic acids"},{"key":"BFncomms14252_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1196\/annals.1348.062","volume":"1082","author":"EW Ng","year":"2006","unstructured":"Ng, E. W. & Adamis, A. P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci. 1082, 151\u2013171 (2006).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFncomms14252_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng, E. W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms14252_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/art.30138","volume":"63","author":"N Mor-Vaknin","year":"2011","unstructured":"Mor-Vaknin, N. et al. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum. 63, 556\u2013567 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFncomms14252_CR6","doi-asserted-by":"publisher","first-page":"9484","DOI":"10.1128\/MCB.01030-06","volume":"26","author":"N Mor-Vaknin","year":"2006","unstructured":"Mor-Vaknin, N. et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol. Cell Biol. 26, 9484\u20139496 (2006).","journal-title":"Mol. Cell Biol."},{"key":"BFncomms14252_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1101\/gad.2036411","volume":"25","author":"F Kappes","year":"2011","unstructured":"Kappes, F. et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev. 25, 673\u2013678 (2011).","journal-title":"Genes Dev."},{"key":"BFncomms14252_CR8","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1073\/pnas.1220751110","volume":"110","author":"AK Saha","year":"2013","unstructured":"Saha, A. K. et al. Intercellular trafficking of the nuclear oncoprotein DEK. Proc. Natl Acad. Sci. USA 110, 6847\u20136852 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms14252_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N","volume":"41","author":"X Dong","year":"1998","unstructured":"Dong, X. et al. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum. 41, 1505\u20131510 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFncomms14252_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D","volume":"43","author":"X Dong","year":"2000","unstructured":"Dong, X. et al. Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum. 43, 85\u201393 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFncomms14252_CR11","first-page":"401","volume":"18","author":"W Szer","year":"1991","unstructured":"Szer, W., Sierakowska, H. & Szer, I. S. Antinuclear antibody profile in juvenile rheumatoid arthritis. J. Rheumatol. 18, 401\u2013408 (1991).","journal-title":"J. Rheumatol."},{"key":"BFncomms14252_CR12","first-page":"2136","volume":"21","author":"IS Szer","year":"1994","unstructured":"Szer, I. S., Sierakowska, H. & Szer, W. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J. Rheumatol. 21, 2136\u20132142 (1994).","journal-title":"J. Rheumatol."},{"key":"BFncomms14252_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532\u20131535 (2004).","journal-title":"Science"},{"key":"BFncomms14252_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4049\/jimmunol.1100450","volume":"187","author":"E Villanueva","year":"2011","unstructured":"Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538\u2013552 (2011).","journal-title":"J. Immunol."},{"key":"BFncomms14252_CR15","doi-asserted-by":"publisher","first-page":"178ra140","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra140 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFncomms14252_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.127.3301.756-a","volume":"127","author":"FJ Di Carlo","year":"1958","unstructured":"Di Carlo, F. J. & Fiore, J. V. On the composition of zymosan. Science 127, 756\u2013757 (1958).","journal-title":"Science"},{"key":"BFncomms14252_CR17","doi-asserted-by":"publisher","first-page":"R370","DOI":"10.1186\/ar1494","volume":"7","author":"ME Frasnelli","year":"2005","unstructured":"Frasnelli, M. E., Tarussio, D., Chobaz-Peclat, V., Busso, N. & So, A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res. Ther. 7, R370\u2013R379 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFncomms14252_CR18","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2011-10-383083","volume":"119","author":"RI Koleva","year":"2012","unstructured":"Koleva, R. I. et al. C\/EBPalpha and DEK coordinately regulate myeloid differentiation. Blood 119, 4878\u20134888 (2012).","journal-title":"Blood"},{"key":"BFncomms14252_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.aaa8064","volume":"349","author":"A Warnatsch","year":"2015","unstructured":"Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316\u2013320 (2015).","journal-title":"Science"},{"key":"BFncomms14252_CR20","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.4049\/jimmunol.1201719","volume":"189","author":"MJ Kaplan","year":"2012","unstructured":"Kaplan, M. J. & Radic, M. Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol. 189, 2689\u20132695 (2012).","journal-title":"J. Immunol."},{"key":"BFncomms14252_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2003.012211","volume":"63","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63, 373\u2013381 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFncomms14252_CR22","first-page":"24","volume":"13","author":"P Olszowy","year":"2015","unstructured":"Olszowy, P., Donnelly, M. R., Lee, C. & Ciborowski, P. Profiling post-translational modifications of histones in human monocyte-derived macrophages. Proteomescience 13, 24 (2015).","journal-title":"Proteomescience"},{"key":"BFncomms14252_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2249.1993.tb08214.x","volume":"94","author":"H Sierakowska","year":"1993","unstructured":"Sierakowska, H., Williams, K. R., Szer, I. S. & Szer, W. The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis. Clin. Exp. Immunol. 94, 435\u2013439 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"BFncomms14252_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1083\/jcb.201203170","volume":"198","author":"V Brinkmann","year":"2012","unstructured":"Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps: is immunity the second function of chromatin? J. Cell. Biol. 198, 773\u2013783 (2012).","journal-title":"J. Cell. Biol."},{"key":"BFncomms14252_CR25","first-page":"560","volume":"24","author":"KJ Murray","year":"1997","unstructured":"Murray, K. J. et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J. Rheumatol. 24, 560\u2013567 (1997).","journal-title":"J. Rheumatol."},{"key":"BFncomms14252_CR26","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/MCB.01921-07","volume":"28","author":"F Kappes","year":"2008","unstructured":"Kappes, F. et al. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol. Cell Biol. 28, 3245\u20133257 (2008).","journal-title":"Mol. Cell Biol."},{"key":"BFncomms14252_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","volume":"183","author":"PT Nash","year":"2005","unstructured":"Nash, P. T. & Florin, T. H. Tumour necrosis factor inhibitors. Med. J. Aust. 183, 205\u2013208 (2005).","journal-title":"Med. J. Aust."},{"key":"BFncomms14252_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.20953","volume":"52","author":"DJ Lovell","year":"2005","unstructured":"Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283\u20131286 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFncomms14252_CR29","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1073\/pnas.0909927107","volume":"107","author":"A Hakkim","year":"2010","unstructured":"Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813\u20139818 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms14252_CR30","doi-asserted-by":"publisher","first-page":"e48111","DOI":"10.1371\/journal.pone.0048111","volume":"7","author":"RS Keshari","year":"2012","unstructured":"Keshari, R. S. et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One 7, e48111 (2012).","journal-title":"PLoS One"},{"key":"BFncomms14252_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.27841","volume":"62","author":"H Huang","year":"2015","unstructured":"Huang, H. et al. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 62, 600\u2013614 (2015).","journal-title":"Hepatology"},{"key":"BFncomms14252_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nm.3547","volume":"20","author":"C Schauer","year":"2014","unstructured":"Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511\u2013517 (2014).","journal-title":"Nat. Med."},{"key":"BFncomms14252_CR33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","volume":"9","author":"AD Keefe","year":"2010","unstructured":"Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537\u2013550 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms14252_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.4049\/jimmunol.166.2.1214","volume":"166","author":"JM Woods","year":"2001","unstructured":"Woods, J. M. et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J. Immunol. 166, 1214\u20131222 (2001).","journal-title":"J. Immunol."},{"key":"BFncomms14252_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev.med.56.062904.144915","volume":"56","author":"SM Nimjee","year":"2005","unstructured":"Nimjee, S. M., Rusconi, C. P. & Sullenger, B. A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555\u2013583 (2005).","journal-title":"Annu. Rev. Med."},{"key":"BFncomms14252_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.gt.3302900","volume":"14","author":"NS Que-Gewirth","year":"2007","unstructured":"Que-Gewirth, N. S. & Sullenger, B. A. Gene therapy progress and prospects: RNA aptamers. Gene ther. 14, 283\u2013291 (2007).","journal-title":"Gene ther."},{"key":"BFncomms14252_CR37","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1128\/MCB.24.13.6011-6020.2004","volume":"24","author":"F Kappes","year":"2004","unstructured":"Kappes, F. et al. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol. Cell Biol. 24, 6011\u20136020 (2004).","journal-title":"Mol. Cell Biol."},{"key":"BFncomms14252_CR38","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.4049\/jimmunol.181.5.3690","volume":"181","author":"M Zhang","year":"2008","unstructured":"Zhang, M., Berndt, B. E., Chen, J. J. & Kao, J. Y. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell\/tumor fusion vaccine efficacy. J. Immunol. 181, 3690\u20133697 (2008).","journal-title":"J. Immunol."},{"key":"BFncomms14252_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2004-08-3323","volume":"106","author":"CH Serezani","year":"2005","unstructured":"Serezani, C. H., Aronoff, D. M., Jancar, S., Mancuso, P. & Peters-Golden, M. Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 106, 1067\u20131075 (2005).","journal-title":"Blood"},{"key":"BFncomms14252_CR40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/srep01045","volume":"3","author":"N Mor-Vaknin","year":"2013","unstructured":"Mor-Vaknin, N. et al. Murine colitis is mediated by vimentin. Sci. Rep. 3, 1045 (2013).","journal-title":"Sci. Rep."},{"key":"BFncomms14252_CR41","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/ar3055","volume":"12","author":"JH Ruth","year":"2010","unstructured":"Ruth, J. H. et al. Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res. Ther. 12, R118 (2010).","journal-title":"Arthritis Res. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms14252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms14252","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms14252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:02:38Z","timestamp":1671753758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms14252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,28]]}},"alternative-id":["BFncomms14252"],"URL":"https:\/\/doi.org\/10.1038\/ncomms14252","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]},"assertion":[{"value":"9 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14252"}}